Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions Post Traumatic Stress Disorder PTSD
Phase NA
Enrollment 64
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to evaluate whether computer-based brain training can help adults with post-traumatic stress disorder (PTSD). Individuals with PTSD often experience difficulties with memory, attention, concentration, and problem-solving, which can significantly affect their daily lives, work performance, and overall quality of life. These cognitive challenges can hinder trauma recovery and reduce the effectiveness of standard PTSD treatments. The main questions this study seeks to address are: Does specialized brain training improve PTSD symptoms compared to regular computer games? Does brain training enhance cognitive functions such as memory, attention, processing speed, and executive functioning? Does brain training improve quality of life and daily functioning? Do participants' self-efficacy and perceived social support influence treatment outcomes? Researchers will compare two approaches: a specialized cognitive training program (HAPPYneuron Pro) with strategy teachings and quality-of-life discussions, versus engaging computer games with quality-of-life discussions, to determine which is more effective for people with PTSD. Study Design Participants will be randomly assigned to one of two groups for an 8-week program: Cognitive remediation training group: Complete computerized cognitive exercises and strategy teachings specifically designed to strengthen memory, attention, and executive functions, combined with quality-of-life discussions. Control group: Complete engaging computer games combined with quality-of-life discussions. Schedule Both groups will follow the same schedule: One online session per week, in small and consistent groups of 4-8 participants. Each 60-minute session consists of 30 minutes of computer activities followed by 45 minutes of group discussion. One at-home individual homework exercise per week (30 minutes at home). Total time commitment: 1h45 per week for 8 weeks. Assessments All participants will complete three comprehensive assessment sessions: before treatment, immediately after the 8-week program, and 3 months later. Assessments include neuropsychological testing and questionnaires on PTSD symptoms, depression, anxiety, quality of life, satisfaction with life, social support, cognitive failures, and self-efficacy. Significance This research evaluates a new, accessible and remotely deliverable approach for PTSD treatment. Current evidence-based treatments often do not directly target the cognitive impairments experienced by many individuals with PTSD. Compensation Participants will receive $35 for each completed assessment (maximum $105). Control group participants will gain access to the cognitive remediation training program after completing their participation.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Behavioral: Cognitive Remediation Training — Cognitive Remediation Training: Eight-week remote program using HAPPYneuron Pro software targeting attention, verbal memory, processing speed, and executive functions. Participants attend weekly 75-minute group sessions (four to eight participants) via videoconferencing: 30 minutes of computerized cognitive exercises and 45 minutes of guided discussion on metacognitive strategies and quality-of-life topics. Weekly homework assignments (45 minutes) reinforce skills. Sessions target attention (selective, sustained, divided), verbal memory (encoding, recall, recognition), and executive functions (planning, problem-solving, cognitive flexibility, inhibition). Strategy teachings address attention, verbal memory, planning, problem-solving, emotion regulation, meditation, and cognitive flexibility. Quality of life discussions (summarized format) cover sleep, nutrition, physical activity, social support, cultural activities, nature-based activities, relaxation, and substance use behaviors.
  • Other: Control Group — Video Games with Quality of Life Support: Eight-week active control program combining commercial video games with quality of life discussions. Participants will attend weekly 75-minute group sessions via secure videoconferencing (four to eight participants) , consisting of 30 minutes of entertaining computer games from the Poki.com platform (games include Bubbles, Sweet World, Minesweeper, etc.) and 45 minutes of group discussions on healthy lifestyle topics including sleep, nutrition, physical activity, social support, cultural activities, nature-based activities, relaxation, and substance use behaviors. Weekly individual gaming assignments (30 minutes) maintain engagement. Games are selected for entertainment value without proven cognitive benefits. Discussions focus on general wellness and lifestyle factors rather than cognitive strategy development.

Primary Outcomes

  • Satisfaction with Life Scale (Baseline (Week 0), Post-intervention (Week 8), 3-month follow-up (Week 20))
  • Cognitive Failures Questionnaire (Baseline (Week 0), Post-intervention (Week 8), 3-month follow-up (Week 20))
  • World Health Organization Quality of Life Scale-Brief (Baseline (Week 0), Post-intervention (Week 8), 3-month follow-up (Week 20))
  • Multidimensional Scale of Perceived Social Support (Baseline (Week 0), Post-intervention (Week 8), 3-month follow-up (Week 20))
  • General Self-Efficacy Scale (Baseline (Week 0), Post-intervention (Week 8), 3-month follow-up (Week 20))
  • Self-Efficacy Scale for Cognitive Remediation Therapy (Baseline (Week 0), Post-intervention (Week 8), 3-month follow-up (Week 20))
  • Continuous Performance Test with Rapid Automatized Naming (Baseline (Week 0), Post-intervention (Week 8), 3-month follow-up (Week 20))
  • Visual Search Task (Baseline (Week 0), Post-intervention (Week 8), 3-month follow-up (Week 20))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-08-03
Completion: 2026-12
Eligibility
Age: 18 Years – 45 Years
Sex: ALL
Volunteers: false
Enrollment: 64 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Université du Québec a Montréal
Contact Information
Study Contact:
Pascale Brillon Principal Investigator, Ph.D.
(514) 987-3000
brillon.pascale@uqam.ca
Pascale Brillon Principal Investigator
(514) 987-3000
brillon.pascale@uqam.ca
Pavillon Adrien-Pinard (SU)
Interventions
  • Behavioral: Cognitive Remediation Training — Cognitive Remediation Training: Eight-week remote program using HAPPYneuron Pro software targeting attention, verbal memory, processing speed, and executive functions. Participants attend weekly 75-minute group sessions (four to eight participants) via videoconferencing: 30 minutes of computerized cognitive exercises and 45 minutes of guided discussion on metacognitive strategies and quality-of-life topics. Weekly homework assignments (45 minutes) reinforce skills. Sessions target attention (selective, sustained, divided), verbal memory (encoding, recall, recognition), and executive functions (planning, problem-solving, cognitive flexibility, inhibition). Strategy teachings address attention, verbal memory, planning, problem-solving, emotion regulation, meditation, and cognitive flexibility. Quality of life discussions (summarized format) cover sleep, nutrition, physical activity, social support, cultural activities, nature-based activities, relaxation, and substance use behaviors.
  • Other: Control Group — Video Games with Quality of Life Support: Eight-week active control program combining commercial video games with quality of life discussions. Participants will attend weekly 75-minute group sessions via secure videoconferencing (four to eight participants) , consisting of 30 minutes of entertaining computer games from the Poki.com platform (games include Bubbles, Sweet World, Minesweeper, etc.) and 45 minutes of group discussions on healthy lifestyle topics including sleep, nutrition, physical activity, social support, cultural activities, nature-based activities, relaxation, and substance use behaviors. Weekly individual gaming assignments (30 minutes) maintain engagement. Games are selected for entertainment value without proven cognitive benefits. Discussions focus on general wellness and lifestyle factors rather than cognitive strategy development.
Study Locations (1 sites)
Pavillon Adrien-Pinard (SU), Montreal, Quebec H2X 3P2 Canada
Eligibility Criteria
Inclusion Criteria * Age 18 to 45 years * Able to speak and read French fluently * Access to a computer with a camera and a secure Internet connection * Access to a private space for assessment and intervention sessions * Available for the complete treatment protocol * Confirmed current PTSD diagnosis using the Structured Clinical Interview for DSM-5 (SCID-5) * Residing in Canada Exclusion Criteria * History of neurological disorders (stroke, intracranial surgery, aneurysm, epilepsy) * Moderate to severe traumatic brain injury OR hospitalization due to traumatic brain injury * Mild traumatic brain injury less than 6 months ago with persistent symptoms * Psychotic disorders * Alcohol abuse or substance dependence disorders * Video game addiction * Hospitalization for major depression or suicide risk within the past 3 months * Regular use of medications that impact neurocognition, including: benzodiazepines (diazepam, lorazepam, alprazolam, Ativan, Xanax, Rivotril) * Residence outside Canada
Conditions Heart Diseases, Type2 Diabetes, Hyperten...
Phase Not Applicable
Enrollment 2500
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

The overall goal is to identify trends and longitudinal associations in psychosocial, food-related, and cardiometabolic risk factors that can guide public health priorities and future research needs aimed at reducing cardiovascular-related disparities in Puerto Rico. To this end, investigators will establish 'PROSPECT: Puerto Rico Observational Study of Psychosocial, Environmental, and Chronic disease Trends', an island-wide, longitudinal population cohort of 2,500 adults (30-75 years) in PR recruited with a community-wide sampling strategy, and assessed in a network of several partner clinics across the island. The study will collect comprehensive data on multiple psychosocial, dietary, and food-related factors, CVD biological markers, and medical record data, with follow-up at 2-years, and will assess variations by urban-rural area and by timing before-after Maria.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Number of participants with self-reported medically-diagnosed chronic diseases (4 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2019-03-01
Completion: 2029-04-30
Eligibility
Age: 30 Years – 75 Years
Sex: ALL
Volunteers: true
Enrollment: 2500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Harvard School of Public Health (HSPH)
Collaborators: National Heart, Lung, and Blood Institute (NHLBI), National Institute on Minority Health and Health Disparities (NIMHD), University of Massachusetts, Lowell, San Diego State University, Albert Einstein College of Medicine, Puerto Rico Consortium for Clinical Investigations
Contact Information
Study Contact:
Josiemer Mattei, PhD
6174323017
jmattei@hsph.harvard.edu
Martha Tamez, ScD
6174323017
m.tamez@mail.harvard.edu
Jonathan Orozco, MS
(787) 930-3257
jonathan.orozco@prcci.org
Puerto Rico Consortium for Clinical Investigation
Interventions
N/A
Study Locations (1 sites)
Puerto Rico Consortium for Clinical Investigation, San Juan, 00927 Puerto Rico
Eligibility Criteria
Inclusion Criteria: 1. Age 30-75 years old at the time of enrollment 2. Non-institutionalized 3. Living in PR at the time of the first interview and the year before and not planning to move from the island within 3 years 4. Able to answer questions without assistance 5. Living in a stable dwelling Exclusion Criteria:
Conditions Depression, Suicide Risk
Phase Not Applicable
Enrollment 1000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

Background: More than 12,000 people have taken part in research at the Experimental Therapeutics \& Pathophysiology Branch at the National Institute of Mental Health Intramural Program. This has led to advances in the treatment of depression, bipolar disorder, and suicide risk. Researchers want to follow up with this group to see if they continue to have mental health symptoms and receive psychiatric treatments. Objective: To learn the long-term impact of depression, bipolar disorder, and suicide risk. Eligibility: Adults ages 18 and older who signed consent for Protocol 01-M-0254 over a year ago. Design: This study has 2 phases: an online phase and a telephone phase. It has no in-person or face-to-face contact. In Phase 1, participants will fill out online surveys. They will access the surveys through the study website. The questions will focus on their current thoughts and feelings. The surveys will also ask about their current treatments for their mental health symptoms. At the end of the surveys, they will be asked if they would like to take part in Phase 2. If so, they will mark yes. Phase 2 includes a phone interview. They will be contacted by email to schedule the interview. In Phase 2, participants will be asked more in-depth questions about how they are feeling. They will also be asked which psychiatric medicines and treatments they have used since they left NIH. In both phases, participants can skip any questions they do not want to answer. The online surveys will take 30 minutes to complete. The phone interview will last 1-4 hours. The information that participants give in this study may be linked to their other NIH research records.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Score on Beck Depression Inventory (suicide item removed) (Follow-up assessment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2021-08-17
Completion: 2028-10-01
Eligibility
Age: 18 Years – 99 Years
Sex: ALL
Volunteers: true
Enrollment: 1000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Institute of Mental Health (NIMH)
Principal Investigators:
  • Elizabeth D Ballard, Ph.D. (PRINCIPAL_INVESTIGATOR) - National Institute of Mental Health (NIMH)
Contact Information
Study Contact:
Elizabeth D Ballard, Ph.D.
(301) 435-9399
elizabeth.ballard@nih.gov
Elizabeth Ballard, Ph.D.
301-435-9399
elizabeth.ballard@nih.gov
National Institutes of Health Clinical Center
Interventions
N/A
Study Locations (1 sites)
National Institutes of Health Clinical Center, Bethesda, Maryland 20892 United States
Eligibility Criteria
* INCLUSION CRITERIA: In order to be eligible to participate in this study, an individual must meet all of the following criteria: 1. Participants who signed consent for Protocol 01-M-0254: The Evaluation of Patients with Mood and Anxiety Disorders and Healthy Volunteers over a year ago. 2. Age 18 years or older 3. Able to provide informed consent online using study website or over the telephone 4. Able to read and write English EXCLUSION CRITERIA: None.
Conditions Glaucoma, Open Angle
Phase NA
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

cyclodiode versus trabeculectomy with MMC in pseudophakic patients.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Procedure: Trabeculectomy — Trabeculectomy with mitomycin c application
  • Procedure: Slow coagulation trans-scleral cyclophotocoagulation — Slow coagulation trans-scleral cyclophotocoagulation

Primary Outcomes

  • evaluate and compare the amount of iop reduction between SC-TSCPC and trabeculectomy with MMC in the management of medically uncontrolled OAG in pseudophakic eyes. (6 months)
  • evaluate and compare the degree of safety of SC-TSCPC versus trabeculectomy with MMC in the management of medically uncontrolled OAG in pseudophakic eyes. (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-07-20
Completion: 2026-12-30
Eligibility
Age: 40 Years and older
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Minia University
Principal Investigators:
  • Ahmed M Eid, MD (STUDY_DIRECTOR) - Minia University Hospital
Contact Information
Study Contact:
Hazem M Abdelaziz, Master
01010045499
hazem.m.abdelaziz@mu.edu.eg
Mohamed Tarek M Abdelkader, MD
01028218703
Hazem M Abdelaziz
01117782048
hazem.m.abdelaziz@mu.edu.eg
Minia University Hospital
Interventions
  • Procedure: Trabeculectomy — Trabeculectomy with mitomycin c application
  • Procedure: Slow coagulation trans-scleral cyclophotocoagulation — Slow coagulation trans-scleral cyclophotocoagulation
Study Locations (1 sites)
Minia University Hospital, Minya, 61111 Egypt
Eligibility Criteria
Inclusion Criteria: * 1\. Patients above 40 years old. 2\. POAG who underwent previous uncomplicated cataract surgery with intraocular lens implantation. 3\. Pseudophakic patients with medically uncontrolled glaucoma in spite of the use of two anti-glaucoma medications or intolerance to medical therapy. 4\. Visual field defects in both the superior and inferior hemi-fields outside the central 5 degrees of fixation. 5\. Mean deviation on perimetry ranges between -6 dB and -12 dB Exclusion Criteria: * 1\. Patients with history of previous glaucoma surgery. 2. Patients who have used topical steroids within the last three months. 3. Patients with significant media opacity, such as corneal opacity, that obstructs fundoscopic examination. 4\. Patients with ocular diseases as uveitis. 5. Patients with severe ocular surface disorders as ocular cicatricial pemphigoid. 6\. Aphakic patients. 7. Ocular interventions apart from YAG posterior capsulotomy.
Conditions Retinitis Pigmentosa (RP), Rod Cone Dyst...
Phase NA
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

This pilot clinical trial evaluates whether non-invasive brain stimulation improves the orientation and mobility (O\&M) skills of individuals with constricted visual fields in both eyes. The study is composed of three visits. The first visit is meant to confirm eligibility by performing a few clinical tests. Eligible participants will then complete two additional visits, one in which the participants receive active stimulation, and one in which the participants receive placebo (sham) stimulation. Stimulation will be administered in a randomized, double-blind order. To evaluate improvement, various measures of O\&M performance will be assessed on a standardized obstacle course featuring static natural and artificial obstacles at defined intervals after the intervention. We hypothesize that the application of hf-tRNS to V1 will improve the orientation and mobility skills of individuals with constricted visual fields immediately following stimulation as a results of enhanced periphery through modulation of the mechanisms responsible for crowding, thereby reducing crowding effects and improving contrast for individuals with rod-cone dystrophy and RP (genetic conditions), whereas for individuals with glaucoma (a neurogenerative condition), any improvement noted would be attributed to be enhanced processing of visual signal in the affected periphery. The results will inform the design of a future, larger-scale study.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Device: Active hf-tRNS. — Active hf-tRNS: A weak alternating electric current is applied to the head through two electrodes to affect the cortical excitability of the targeted cells in the brain. Stimulation instrument: neuroConn DC Stimulator Plus 2019 (Direct current stimulator Model number 0021, power: 1.2 W, charger: 2.9 V (maximum 160 mA)) (neurocaregroup.com), or neuroConn DC Stimulator MC 2016 (Multi-channel stimulator Model number 0028, power: 24 W, rating: 12 V (maximum 2 A)) (neurocaregroup.com).
  • Device: Placebo/sham hf-tRNS — Placebo/sham hf-tRNS: The tRNS machine will be used as in active stimulation, except the electrical current will not be applied. Stimulation instrument: neuroConn DC Stimulator Plus 2019 (Direct current stimulator Model number 0021, power: 1.2 W, charger: 2.9 V (maximum 160 mA)) (neurocaregroup.com), or neuroConn DC Stimulator MC 2016 (Multi-channel stimulator Model number 0028, power: 24 W, rating: 12 V (maximum 2 A)) (neurocaregroup.com).

Primary Outcomes

  • Percentage preferred walking speed (PPWS) (The pre-test and post-tests will take roughly 2 hours to complete.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-07-01
Completion: 2027-08-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Waterloo
Collaborators: The Hong Kong Polytechnic University
Principal Investigators:
  • Benjamin Thompson, PhD (PRINCIPAL_INVESTIGATOR) - University of Waterloo
Contact Information
Study Contact:
Benjamin Thompson, PhD
1+5198884567
ben.thompson@uwaterloo.ca
Melanie A Mungalsingh, PhD
melanie.mungalsingh@uwaterloo.ca
Benjamin Thompson, PhD
1+15198884567
ben.thompson@uwaterloo.ca
University of Waterloo, School of Optometry and Vision Science
Interventions
  • Device: Active hf-tRNS. — Active hf-tRNS: A weak alternating electric current is applied to the head through two electrodes to affect the cortical excitability of the targeted cells in the brain. Stimulation instrument: neuroConn DC Stimulator Plus 2019 (Direct current stimulator Model number 0021, power: 1.2 W, charger: 2.9 V (maximum 160 mA)) (neurocaregroup.com), or neuroConn DC Stimulator MC 2016 (Multi-channel stimulator Model number 0028, power: 24 W, rating: 12 V (maximum 2 A)) (neurocaregroup.com).
  • Device: Placebo/sham hf-tRNS — Placebo/sham hf-tRNS: The tRNS machine will be used as in active stimulation, except the electrical current will not be applied. Stimulation instrument: neuroConn DC Stimulator Plus 2019 (Direct current stimulator Model number 0021, power: 1.2 W, charger: 2.9 V (maximum 160 mA)) (neurocaregroup.com), or neuroConn DC Stimulator MC 2016 (Multi-channel stimulator Model number 0028, power: 24 W, rating: 12 V (maximum 2 A)) (neurocaregroup.com).
Study Locations (1 sites)
University of Waterloo, School of Optometry and Vision Science, Waterloo, Ontario N2L 3G1 Canada
Eligibility Criteria
Inclusion Criteria: * Are healthy, capacitated adults with binocular constricted visual field loss (due to either retinitis pigmentosa (RP), rod-cone dystrophy, or advanced glaucoma) resulting in functional vision losses. These individuals with visual impairments can be those who have been previously trained by an Orientation and Mobility (O\&M) specialist to independently travel with the long white cane daily (since the length of the white cane and tip at the base are based on personal preference, they should be willing to use their own white cane for the study), and those who do not necessarily use a cane for travelling. * Have binocular visual acuity or best corrected binocular visual acuity no worse than 6/12 or 20/40 or +0.30 logMAR (inclusive) with no eccentric viewing and binocular visual fields no better than 50 degrees in total in each eye as given by the Humphrey Field analyzer and no better than 50 degrees binocularly as given by arc perimeter test. The Humphrey Field Analyzer measures static visual field test, whereas the Arc perimeter test measures kinetic visual field test. Measuring kinetic and static visual field would promote a greater understanding of the individual's daily performance. * Are over the age of 18 (inclusive) and has full legal capacity to provide informed consent. * Have read and fully comprehends the information in the consent letter. * Are willing and capable of adhering to instructions and maintaining the outlined appointment schedule. Exclusion Criteria: * Are involved in other recent eye-related studies, either clinical or research-related. To be eligible they would have to wait at least one week for studies not involving brain stimulation, and four weeks for studies in which they receive brain stimulation before they could participate in this study. * Have been diagnosed with dementia or self-reported dementia with no formal diagnosis. * Have been diagnosed with a cognitive impairment or self-reported cognitive impairment with no formal diagnosis. * Have been diagnosed with physical or motor impairments resulting in walking and/or balancing issues or self-reported physical or motor impairments resulting in walking and/or balancing issues with no formal diagnosis. * Have been diagnosed with vestibular disorders or dysfunctions which affects one's balance and/or mobility or self-reported vestibular disorders or dysfunctions which affects one's balance and/or mobility with no formal diagnosis. * Are unable to follow the researcher's instructions. * Are anticipating treatment (including ocular surgery) for any eye disease within the duration of the study. * Have any ocular pathology in addition to retinitis pigmentosa (RP), rod-cone dystrophy, or advanced glaucoma, which can diminish their visual acuity and/or their visual field, however wearing glasses or contact lenses, as well as mild cataract of grade 2 or below is acceptable. * Have severe hearing impairment. * Are pregnant or trying to get pregnant. * Fit any of the typical contraindicators for brain stimulation. See contraindicator section below. For all participants the contraindications for brain stimulation are: * Diagnosed with epilepsy or have previously experienced an epileptic seizure. * Implanted medication pump or implanted electronic device, including defibrillator or pacemaker. * Any metal implants in the head (excluding tooth fillings). * Active electric implants anywhere in the body (especially the head region). * On psychoactive medication for any psychiatric or neurological conditions including but not limited to depression and schizophrenia. * Areas of sensitive skin located on the face or head, or a skin condition on the face, or regularly use medication to alleviate skin irritation on the face. * Recurring headaches. * Previous head injury or skull fracture or head/brain surgery. * Heart disease, neurological condition, or a history of cardiac or neurological surgery. * Current or historical cancerous or noncancerous brain tumor, or other abnormalities in brain structure.
Conditions Pulmonary Hypertension, Pulmonary Hypert...
Phase PHASE2
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn about the safety and efficacy of Pioglitazone in people with Pulmonary Hypertension (PH) due to Chronic Lung Disease (CLD). The main question it aims to answer is: • Whether pioglitazone affects mitochondrial oxygen utilization in patients with PH due to CLD. Participants will be asked to take pioglitazone or placebo once daily for 28 days followed by a washout period of 2 weeks followed by 28 days of the other study drug (participants randomized to placebo followed by pioglitazone or pioglitazone followed by placebo).

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Crossover Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: Pioglitazone 30mg — Study participants will take Pioglitazone 30 mg PO daily
  • Drug: Placebo — Study participants will take a placebo PO daily
  • Diagnostic Test: Labs — Labs will be performed for Urine HCG, Complete Blood count (CBC), Chemistry Panel, Fasting lipids, insulin, glucose, and Bioenergetic analysis (platelets).

Primary Outcomes

  • Change in Mitochondrial metabolism parameters: Spare respiratory capacity (Day 1, Day 28, Day 70)
  • Change in Mitochondrial metabolism parameters: Maximal respiration (Day 1, Day 28, Day 70)
  • Change in Mitochondrial metabolism parameters: Basal respiration (Day 1, Day 28, Day 70)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-12-17
Completion: 2028-02
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Emory University
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigators:
  • Aaron Trammell (PRINCIPAL_INVESTIGATOR) - Emory University
Contact Information
Study Contact:
Aaron Trammell, MD, MSc
404-712-8204
awtramm@emory.edu
Jane Gillespie, RN
404-712-8204
jegille@emory.edu
Jane Gillespie, RN
404-712-8204
jegille@emory.edu
Emory Healthcare System
Interventions
  • Drug: Pioglitazone 30mg — Study participants will take Pioglitazone 30 mg PO daily
  • Drug: Placebo — Study participants will take a placebo PO daily
  • Diagnostic Test: Labs — Labs will be performed for Urine HCG, Complete Blood count (CBC), Chemistry Panel, Fasting lipids, insulin, glucose, and Bioenergetic analysis (platelets).
Study Locations (1 sites)
Emory Healthcare System, Atlanta, Georgia 30322 United States
Eligibility Criteria
Inclusion Criteria: * Provision of a signed and dated informed consent form * Stated willingness to comply with all study procedures for the duration of the study * Confirmed to have pulmonary hypertension (PH) due to chronic lung disease at screening * Pulmonary hypertension is defined based on meeting all three of the following measured at rest during the RHC: * Mean pulmonary artery pressure \>20 mmHg * Pulmonary artery wedge pressure ≤15 mmHg * Pulmonary vascular resistance \> 2 Wood units * Pulmonary hypertension is classified in Group 3: PH associated with lung diseases and/or hypoxia * Medications approved for the treatment of pulmonary hypertension must be at a stable dose for at least 30 days * Ability to take oral medication and be willing to adhere to the study intervention regimen * For females of reproductive potential: agreement to use highly effective contraception during study participation and for an additional 4 weeks after the end of study participation. * For males of reproductive potential: use of condoms or other methods to ensure effective contraception with a partner * Agreement to adhere to Lifestyle Considerations (below) throughout the study duration o During this study, participants are asked to arrive in the clinic for study visits in the fasting state. Specifically, participants should abstain from any caloric intake for 6 hours before arrival for the study visit. Exclusion Criteria: * Diabetes mellitus (type 1 or type 2), present within the preceding 1 year * Personal history of symptomatic hypoglycemia within 90 days preceding enrollment * Personal outpatient use of pioglitazone, rosiglitazone, metformin, insulin, or other medications for the indication of diabetes within 90 days preceding enrollment * History of left ventricular failure (systolic or diastolic) * Pulmonary hypertension due to Group 2 PH (PH due to left heart disease) * History of prior or active bladder cancer * Thrombocytopenia (diagnosis or known platelet count ≤120) within 90 days preceding enrollment * Platelet count ≤120 during screening or on the day of enrollment hypertension due to chronic lung disease * Cystic fibrosis * Pregnancy or lactation * Current tobacco use * Known allergic reaction to components of the study medication (pioglitazone) * Treatment with another investigational drug within 30 days
Conditions Cardiovascular (CV) Risk, Preeclampsia (...
Phase Not Applicable
Enrollment 1260
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

In this project, the investigators aim to study how all these factors determine the cardiovascular status of a total of 1,800 mothers, 3 to 6 years after delivery. In addition, the investigators want to assess whether lifestyle and living conditions after childbirth may improve or worsen this imprint, since women often prioritize their families over themselves, making it more difficult to maintain a healthy lifestyle that could reduce their cardiovascular risk. Furthermore, the investigators will evaluate how environmental exposures influence their health, as well as explore potential strategies for prediction and prevention. The goal is to develop an easy-to-use algorithm or test that allows women and their physicians to assess this risk, ideally in the form of a mobile app. Although predictive algorithms for cardiovascular health already exist, most have been developed using predominantly male or older populations, and none have taken into account pregnancy-related events or environmental exposure - both of which are key determinants of women's cardiovascular health.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Hypertension (3-6 years after index pregnancy)
  • Abnormal cardiac function (3-6 years after index pregnancy)
  • Biochemical cardiac markers (3-6 years after index pregnancy)
  • Coronary artery disease (3-6 years after index pregnancy)
  • Other cardiovascular major events (3-6 years after index pregnancy)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-08-28
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 1260 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Collaborators: Hospital Sant Joan de Deu, Barcelona Institute for Global Health
Principal Investigators:
  • Elisa Llurba, PhD (PRINCIPAL_INVESTIGATOR) - Hospital de la Sant Creu i Sant Pau
Contact Information
Study Contact:
Elisa Llurba Olivé, PhD
+34 935534078
ellurba@santpau.cat
Pablo García Manau, PhD
+34 627813346
pgarciama@santpau.cat
Pablo García Manau, PhD
+34 627813346
pgarciama@santpau.cat
Hospital de la Santa Creu i de Sant Pau
Interventions
N/A
Study Locations (1 sites)
Hospital de la Santa Creu i de Sant Pau, Barcelona, 08025 Spain
Eligibility Criteria
Inclusion Criteria: * Patients who participated in the BiSC (Barcelona Life Study Cohort), EuroPE (Randomized open-label control trial to evaluate if the incorporation of sFlt1/PlGF ratio in the diagnosis and classification of PE improves maternal and perinatal outcomes in women with suspicion of the disease; PI16/00375) and AngioCor (Cardiac dysfunction and remodeling in patients with preeclampsia regulated by antiangiogenic environment: clinical and experimental approach, PI19/00702) cohort studies * Who have delivered within the previous 3-6 years. * Give written consent when invited to participate in this study protocol. Exclusion Criteria: * Unwillingness to participate in this study * Probability of loss to follow-up.
Conditions Pregnancy Related
Phase Not Applicable
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

The single nucleus RNA-seq approach allows the placental transcriptome to be analyzed from nuclei, thus preserving the integrity of placental syncytium. This approach is feasible on small fragments of villi and offers for the first time the possibility to consider the characterization of gene expression within the structural unit of the human placenta during pregnancy (at the 1st trimester and childbirth)

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: Non applicable — Placental transcriptomic analysis

Primary Outcomes

  • Analysis of the cellular transcriptomic trajectory of the human placenta (Day 0)
  • Analysis of the cellular transcriptomic trajectory of the human placenta (At childbirth)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-03-25
Completion: 2029-02
Eligibility
Age: 18 Years – 50 Years
Sex: FEMALE
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Assistance Publique - Hôpitaux de Paris
Collaborators: Institut National de la Santé Et de la Recherche Médicale, France, URC-CIC Paris Descartes Necker Cochin
Principal Investigators:
  • Céline MÉHATS, PHD (STUDY_DIRECTOR) - Institut National de la Santé Et de la Recherche Médicale, France
  • Hélène COLLINOT, MD (PRINCIPAL_INVESTIGATOR) - APHP
Contact Information
Study Contact:
Vassilis TSATSARIS, MD PHD
00331 58 41 38 71
vassilis.tsatsaris@aphp.fr
Marie BENHAMMANI-GODARD
0033158411190
marie.godard@aphp.fr
Hélène COLLINOT, MD
0033 1 58 41 38 19
Maternité Port-Royal, Cochin hospital
Interventions
  • Other: Non applicable — Placental transcriptomic analysis
Study Locations (1 sites)
Maternité Port-Royal, Cochin hospital, Paris, IDF 75014 France
Eligibility Criteria
Inclusion Criteria: * Age 18 to 50 * Progressive monofoetal pregnancy between 11 and 15 weeks of amenorrhea * Patient with prenatal medical indication and requesting chorionic villus biopsy with cytogenetic analysis or molecular genetics * Patient scheduled for delivery at Port-Royal Maternity Hospital Exclusion Criteria: * Minor patient * Multiple pregnancy * Patient's objection * Without health insurance * Patient under guardianship or curatorship
Conditions Hypertension (Without Type 2 Diabetes Me...
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of the study is to determine the effectiveness of wild blueberries on cardiovascular health, cognitive function, and gut microbiota composition in non-Hispanic Black and White adults with elevated blood pressure.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Basic Science Masking/blinding: Triple

Interventions / Regimen

  • Dietary Supplement: Wild Blueberry — Daily consumption of 22 g of freeze-dried wild blueberry freeze-dried powder for 8 weeks
  • Dietary Supplement: Placebo — Daily consumption of 22 g of freeze-dried macronutrient-matched placebo powder for 8 weeks

Primary Outcomes

  • Ambulatory Blood Pressure (Baseline, 4 weeks, and 8 weeks)
  • Pulse Wave Velocity (Baseline, 4 weeks, and 8 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-09-17
Completion: 2027-01-01
Eligibility
Age: 45 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Georgia State University
Principal Investigators:
  • Rafaela G Feresin, PhD (PRINCIPAL_INVESTIGATOR) - Georgia State University
Contact Information
Study Contact:
Rafaela G Feresin, PhD
404-413-1233
berries@gsu.edu
Rafaela Feresin, PhD
404-413-1233
berries@gsu.edu
Georgia State University
Rafaela G Feresin, PhD
Georgia State University
Interventions
  • Dietary Supplement: Wild Blueberry — Daily consumption of 22 g of freeze-dried wild blueberry freeze-dried powder for 8 weeks
  • Dietary Supplement: Placebo — Daily consumption of 22 g of freeze-dried macronutrient-matched placebo powder for 8 weeks
Study Locations (1 sites)
Georgia State University, Atlanta, Georgia 30303 United States
Eligibility Criteria
Inclusion Criteria: * Individuals 45-65 years of age * Diagnosis of elevated blood pressure or stage 1 hypertension (systolic blood pressure = 120-139 mmHg and/or diastolic blood pressure = 80-89 mmHg) for at least 6 months * BMI 25-35 kg/m2 via anthropometric measurements. * Ability to give consent Exclusion Criteria: * Allergies to berries * Use of one hypertensive drug for less than three months * Use of more than one anti-hypertensive or statin drug, insulin, antibiotics, and anti-inflammatory drugs, active cancer, gastrointestinal, renal, cardiovascular, thyroid, and neurological disorders or severe head injury * Smoking * Alcohol consumption (\>2 drinks/day) * Consuming antioxidant, probiotic, and prebiotic supplements * Pregnant or lactating * Participating in a weight loss program
Conditions Preeclampsia Postpartum
Phase PHASE2
Enrollment 86
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this research study is to evaluate the effect of low-dose aspirin on recovery from severe preeclampsia (a high blood pressure disorder of pregnancy) among women who have given birth. We hypothesize that taking aspirin for the first week after giving birth will enhance recovery from preeclampsia by decreasing the levels of a protein called soluble fms-like tyrosine kinase (sFlt-1), which is thought to be a main contributor to the development of preeclampsia, and speeding up return to a normal blood pressure.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Drug: Aspirin 81Mg Ec Tab — Aspirin 81 mg 1 tablet by mouth. Participants randomized to receive aspirin in addition to standard blood pressure management will receive the study medication nightly at 20:00, with first dose initiated within 24 hours of delivery.

Primary Outcomes

  • Reduction in sFlt-1 (1 week postpartum)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2023-07-26
Completion: 2026-12
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 86 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: MemorialCare Health System
Collaborators: University of California, Irvine
Principal Investigators:
  • Megan C Oakes, MD MSCI (PRINCIPAL_INVESTIGATOR) - Miller Children's and Women's Hospital, Long Beach/ MemorialCare Medical Center
Contact Information
Study Contact:
Megan C Oakes, MD MSCI
562-997-8510
moakes2@memorialcare.org
Ashten B Waks, MD MSPH
562-997-8510
awaks@memorialcare.org
Megan Oakes, MD
562-997-8510
moakes2@memorialcare.org
Miller Children's and Women's Hospital, Long Beach/MemorialCare Long Beach
Interventions
  • Drug: Aspirin 81Mg Ec Tab — Aspirin 81 mg 1 tablet by mouth. Participants randomized to receive aspirin in addition to standard blood pressure management will receive the study medication nightly at 20:00, with first dose initiated within 24 hours of delivery.
Study Locations (1 sites)
Miller Children's and Women's Hospital, Long Beach/MemorialCare Long Beach, Long Beach, California 90740 United States
Eligibility Criteria
Inclusion Criteria: * Preeclampsia with severe features diagnosed during delivery admission, as defined by ACOG criteria. * Pre- and postnatal care provided by the Long Beach Memorial Ob/Gyn resident or Maternal-Fetal Medicine clinic. Exclusion Criteria: * Patient age \<18 years old * Non-English or Non-Spanish speaking * Chronic hypertension diagnosed before 20 weeks' gestation * Known allergy, prior adverse reaction, or any medical condition in which aspirin is contraindicated (nasal polyps, gastric or duodenal ulcers, history of gastrointestinal bleeding, severe hepatic dysfunction) * Aspirin prescribed postpartum for any other medical condition * Bleeding disorder * Breastfeeding an infant with thrombocytopenia
Conditions Hypertension
Phase NA
Enrollment 300
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

High blood pressure is a powerful risk factor for heart disease. Black women are more likely to have high blood pressure than white women or Hispanic women. Even when they are aware they have high blood pressure, many people struggle to keep their blood pressure controlled. Research shows a connection between life stress and high blood pressure and heart disease outcomes. Mindfulness training programs can help people regulate their emotions and cope with stress. Research shows that mindfulness programs can also lower blood pressure. This study will compare two programs: MIND-BP, a Zoom-based mindfulness training group; and BOOST, a Zoom-based support group. The aims of the study are to test if the MIND-BP program leads to greater reductions in blood pressure, stress and depressive symptoms than the BOOST program in Black women with high blood pressure who are participating in the Jackson Heart Study. The primary outcome measure is 6-month change in systolic blood pressure. The secondary outcome measures are 6-month changes in perceived stress and depressive symptoms.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Double

Interventions / Regimen

  • Behavioral: MIND-BP — 8-week program delivered to small groups by a trained facilitator using Zoom/Webex. Each session is one hour long and includes a check-in period, teaching on the week's topic, group discussion, a skill-building exercise and home practice assignment. Participants receive a workbook of all session content, audio guides for home practice, and practice logs. At the start of the program, the stress response and its importance for hypertension and cardiovascular disease is discussed, and the rationale for the mindfulness and cognitive skills to be taught are explained. Weekly sessions focus on learning and practicing skills.
  • Behavioral: BOOST — The BOOST program is designed to control for attention, credibility, and expectation of benefit. To parallel MIND-BP, the BOOST program will be delivered in 8 weekly group sessions via Zoom/Webex and led by a trained facilitator. Each weekly BOOST session will be 1 hour long and comprised of a check-in period, introduction of the week's topic, and group discussion. Didactic information, skill-building instruction and home practice are not included. Weekly BOOST session topics include: (1) personal experience of hypertension; (2) personal experience of stress; (3) personal experience of mood-related challenges; (4) personal experience of social relationships; (5) concerns related to hypertension treatment; (6) concerns about other health problems; (7) personal experience related to healthcare; and (8) review of the BOOST experience.

Primary Outcomes

  • Change in Systolic Blood Pressure (Baseline, Month 6)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-11-18
Completion: 2027-05-30
Eligibility
Age: 18 Years – 99 Years
Sex: FEMALE
Volunteers: false
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: NYU Langone Health
Collaborators: National Institute on Minority Health and Health Disparities (NIMHD)
Principal Investigators:
  • Tanya Spruill, PhD (PRINCIPAL_INVESTIGATOR) - NYU Langone Health
Contact Information
Study Contact:
Tanya Spruill, PhD
646-923-0626
Tanya.spruill@nyulangone.org
April P. Carson, PhD
University of Mississippi Medical Center
Interventions
  • Behavioral: MIND-BP — 8-week program delivered to small groups by a trained facilitator using Zoom/Webex. Each session is one hour long and includes a check-in period, teaching on the week's topic, group discussion, a skill-building exercise and home practice assignment. Participants receive a workbook of all session content, audio guides for home practice, and practice logs. At the start of the program, the stress response and its importance for hypertension and cardiovascular disease is discussed, and the rationale for the mindfulness and cognitive skills to be taught are explained. Weekly sessions focus on learning and practicing skills.
  • Behavioral: BOOST — The BOOST program is designed to control for attention, credibility, and expectation of benefit. To parallel MIND-BP, the BOOST program will be delivered in 8 weekly group sessions via Zoom/Webex and led by a trained facilitator. Each weekly BOOST session will be 1 hour long and comprised of a check-in period, introduction of the week's topic, and group discussion. Didactic information, skill-building instruction and home practice are not included. Weekly BOOST session topics include: (1) personal experience of hypertension; (2) personal experience of stress; (3) personal experience of mood-related challenges; (4) personal experience of social relationships; (5) concerns related to hypertension treatment; (6) concerns about other health problems; (7) personal experience related to healthcare; and (8) review of the BOOST experience.
Study Locations (1 sites)
University of Mississippi Medical Center, Jackson, Mississippi 39216 United States
Eligibility Criteria
Inclusion Criteria: * Female participant in Jackson Heart Study * Willing to be randomized and comply with all aspects of protocol * Willing to be audio-recorded during group sessions. Exclusion Criteria: * Positive cognitive screen (MMSE \<19) * Severe depressive symptoms (CES-D ≥16) * Pregnant or planning to become pregnant in the next 6 months * Current participation in another trial * Arm circumference \>45 cm and \<22 cm
Conditions Stroke, Hypertension, Home Blood Pressur...
Phase NA
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

The investigators want to improve care for people who have had a stroke. High blood pressure is the leading cause for having a second stroke and can lead to poor brain health. The goal of this study is to compare two new ways of lowering blood pressure. The first way is to help people check their blood pressure at home. The second way is to bring people together and learn about blood pressure in a group setting. The study team thinks that using both methods together will make it easier to lower blood pressure after a stroke. The study team needs this study to test these two methods together in people who have had a stroke. The investigators believe this is an important study because having high blood pressure makes having another stroke very likely. Therefore, the investigators want to lower blood pressure in people with strokes to keep their brains as healthy as possible and to help with stroke recovery.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: Group medical visits and home blood pressure monitoring — This arm will receive instructions for home blood pressure monitoring but also be enrolled in group medical visits.

Primary Outcomes

  • Systolic Blood Pressure (three months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-09-22
Completion: 2028-04-30
Eligibility
Age: 35 Years and older
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Massachusetts General Hospital
Collaborators: American Heart Association
Contact Information
Study Contact:
Nirupama Yechoor, MD, MSc
857-282-5184
nyechoor@mgh.harvard.edu
Nirupama Yechoor, MD, MSC
8572825184
nyechoor@mgh.harvard.edu
Massachusetts General Hospital
Interventions
  • Behavioral: Group medical visits and home blood pressure monitoring — This arm will receive instructions for home blood pressure monitoring but also be enrolled in group medical visits.
Study Locations (1 sites)
Massachusetts General Hospital, Boston, Massachusetts 02115 United States
Eligibility Criteria
Inclusion Criteria: * Incident, mild to moderate, ischemic or hemorrhagic stroke (NIHSS≤15, ICH score≤3) * history or new diagnosis of hypertension * ability to read and speak English * internet access * established primary care physician at MGH Exclusion Criteria: * severe stroke (NIHSS\>15, ICH score\>3) * discharge location to inpatient rehabilitation or skilled nursing facility * dementia * subjects with moderate to severe aphasia without a caregiver to consent on their behalf